255 related articles for article (PubMed ID: 22624467)
1. [Universal influenza vaccines: developments, prospects for use].
Tsybalova LM; Kiselev OI
Vopr Virusol; 2012; 57(1):9-14. PubMed ID: 22624467
[TBL] [Abstract][Full Text] [Related]
2. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
3. Universal influenza vaccines, a dream to be realized soon.
Zhang H; Wang L; Compans RW; Wang BZ
Viruses; 2014 Apr; 6(5):1974-91. PubMed ID: 24784572
[TBL] [Abstract][Full Text] [Related]
4. Prospects for universal influenza virus vaccine.
Gerhard W; Mozdzanowska K; Zharikova D
Emerg Infect Dis; 2006 Apr; 12(4):569-74. PubMed ID: 16704803
[TBL] [Abstract][Full Text] [Related]
5. Influenza virus-like particle vaccines.
Haynes JR
Expert Rev Vaccines; 2009 Apr; 8(4):435-45. PubMed ID: 19348559
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics design and experimental validation of influenza A virus multi-epitopes that induce neutralizing antibodies.
Ramírez-Salinas GL; García-Machorro J; Rojas-Hernández S; Campos-Rodríguez R; de Oca AC; Gomez MM; Luciano R; Zimic M; Correa-Basurto J
Arch Virol; 2020 Apr; 165(4):891-911. PubMed ID: 32060794
[TBL] [Abstract][Full Text] [Related]
7. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
[TBL] [Abstract][Full Text] [Related]
8. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
9. Influenza virus neuraminidase (NA): a target for antivirals and vaccines.
Jagadesh A; Salam AA; Mudgal PP; Arunkumar G
Arch Virol; 2016 Aug; 161(8):2087-94. PubMed ID: 27255748
[TBL] [Abstract][Full Text] [Related]
10. Immunization with baculovirus displayed H6 hemagglutinin vaccine protects mice against lethal H6 influenza virus challenge.
Musthaq SK; Kumar SR; Szyporta M; Kwang J
Antiviral Res; 2014 Sep; 109():42-53. PubMed ID: 24973759
[TBL] [Abstract][Full Text] [Related]
11. Universal influenza vaccine: the holy grail?
Shaw AR
Expert Rev Vaccines; 2012 Aug; 11(8):923-7. PubMed ID: 23002973
[TBL] [Abstract][Full Text] [Related]
12. [Molecular analyses of human influenza viruses. Circulation of new variants since 1995/96].
Biere B; Schweiger B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Sep; 51(9):1050-60. PubMed ID: 18773168
[TBL] [Abstract][Full Text] [Related]
13. Pandemic preparedness: toward a universal influenza vaccine.
Roose K; Fiers W; Saelens X
Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167
[TBL] [Abstract][Full Text] [Related]
14. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.
Eichelberger MC; Monto AS
J Infect Dis; 2019 Apr; 219(Suppl_1):S75-S80. PubMed ID: 30715357
[TBL] [Abstract][Full Text] [Related]
15. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.
Creytens S; Pascha MN; Ballegeer M; Saelens X; de Haan CAM
Front Immunol; 2021; 12():786617. PubMed ID: 34868073
[TBL] [Abstract][Full Text] [Related]
16. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.
Marcelin G; Sandbulte MR; Webby RJ
Rev Med Virol; 2012 Jul; 22(4):267-79. PubMed ID: 22438243
[TBL] [Abstract][Full Text] [Related]
17. Research and development of universal influenza vaccines.
Du L; Zhou Y; Jiang S
Microbes Infect; 2010 Apr; 12(4):280-6. PubMed ID: 20079871
[TBL] [Abstract][Full Text] [Related]
18. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.
Zharikova D; Mozdzanowska K; Feng J; Zhang M; Gerhard W
J Virol; 2005 Jun; 79(11):6644-54. PubMed ID: 15890902
[TBL] [Abstract][Full Text] [Related]
19. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L
Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017
[TBL] [Abstract][Full Text] [Related]
20. Genetic engineering of live attenuated influenza viruses.
Jin H; Chen Z; Liu J; Kemble G
Methods Mol Biol; 2012; 865():163-74. PubMed ID: 22528159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
